|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,540,981: CGRP Receptor Antagonists for Migraine Treatment
This report analyzes U.S. Patent 11,540,981, focusing on its claims, scope, and the surrounding patent landscape concerning calcitonin gene-related peptide (CGRP) receptor antagonists for migraine treatment. The patent, granted on January 3, 2023, to Bristol-Myers Squibb Company, claims specific crystalline forms of ubrogepant, a known CGRP receptor antagonist.
What Does U.S. Patent 11,540,981 Claim?
U.S. Patent 11,540,981 claims specific crystalline forms of ubrogepant, a small molecule CGRP receptor antagonist developed for the acute treatment of migraine. The patent's primary focus is on polymorphs and solvates of ubrogepant, which can affect a drug's stability, solubility, and bioavailability.
The patent contains 25 claims. Key claims include:
- Claim 1: A crystalline form of ubrogepant, designated as Form I, characterized by a powder X-ray diffraction (PXRD) pattern comprising specific peaks at particular 2-theta angles. The claim lists eleven specific diffraction peaks.
- Claim 2: A crystalline form of ubrogepant, designated as Form II, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists ten specific diffraction peaks.
- Claim 3: A crystalline form of ubrogepant, designated as Form III, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists twelve specific diffraction peaks.
- Claim 4: A crystalline form of ubrogepant, designated as Form IV, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 5: A crystalline form of ubrogepant, designated as Form V, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists eight specific diffraction peaks.
- Claim 6: A crystalline form of ubrogepant, designated as Form VI, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists eight specific diffraction peaks.
- Claim 7: A crystalline form of ubrogepant, designated as Form VII, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 8: A crystalline form of ubrogepant, designated as Form VIII, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 9: A crystalline form of ubrogepant, designated as Form IX, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 10: A crystalline form of ubrogepant, designated as Form X, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 11: A crystalline form of ubrogepant, designated as Form XI, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists eight specific diffraction peaks.
- Claim 12: A crystalline form of ubrogepant, designated as Form XII, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists eight specific diffraction peaks.
- Claim 13: A crystalline form of ubrogepant, designated as Form XIII, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists eight specific diffraction peaks.
- Claim 14: A crystalline form of ubrogepant, designated as Form XIV, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists eight specific diffraction peaks.
- Claim 15: A crystalline form of ubrogepant, designated as Form XV, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists eight specific diffraction peaks.
- Claim 16: A crystalline form of ubrogepant, designated as Form XVI, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 17: A crystalline form of ubrogepant, designated as Form XVII, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 18: A crystalline form of ubrogepant, designated as Form XVIII, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 19: A crystalline form of ubrogepant, designated as Form XIX, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 20: A crystalline form of ubrogepant, designated as Form XX, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 21: A crystalline form of ubrogepant, designated as Form XXI, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists eight specific diffraction peaks.
- Claim 22: A crystalline form of ubrogepant, designated as Form XXII, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 23: A crystalline form of ubrogepant, designated as Form XXIII, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 24: A crystalline form of ubrogepant, designated as Form XXIV, characterized by a PXRD pattern comprising specific peaks at particular 2-theta angles. The claim lists seven specific diffraction peaks.
- Claim 25: A process for preparing ubrogepant Form I, comprising steps to achieve the desired crystalline structure.
The patent also describes various analytical data supporting these crystalline forms, including PXRD patterns, differential scanning calorimetry (DSC) thermograms, and thermogravimetric analysis (TGA) data. The specifications detail methods for preparing these forms, often involving controlled crystallization processes, solvent systems, and temperature parameters.
What Is the Strategic Significance of This Patent?
U.S. Patent 11,540,981 provides Bristol-Myers Squibb (BMS) with significant intellectual property protection for specific crystalline forms of ubrogepant. This type of patent, often referred to as a "polymorph patent," is crucial for extending market exclusivity beyond the initial composition of matter patent.
The development of specific crystalline forms can offer several advantages for a pharmaceutical product:
- Improved Stability: Certain polymorphs can be more stable under storage conditions, leading to a longer shelf life and reduced degradation.
- Enhanced Bioavailability: Crystalline forms can influence a drug's dissolution rate and solubility in the body, potentially improving its absorption and therapeutic efficacy.
- Manufacturing Advantages: Specific crystalline forms may be easier to handle, process, and formulate into dosage forms, leading to more efficient and cost-effective manufacturing.
- Patentability: Novel crystalline forms that exhibit improved properties are patentable even if the active pharmaceutical ingredient (API) itself is already known.
For BMS, this patent solidifies protection for ubrogepant's formulation and manufacturing. It aims to prevent generic competitors from developing and marketing their versions of ubrogepant by targeting different, potentially less advantageous, crystalline forms or by challenging the novelty or inventiveness of existing forms.
The patent's claims are detailed and specific, focusing on the unique X-ray diffraction patterns that identify each crystalline form. This specificity can make it challenging for competitors to design around the patent without infringing.
What Is the Timeline of Ubrogepant's Patent Protection?
Ubrogepant, under the brand name Ubrelvy, was developed by Allergan, which was subsequently acquired by AbbVie. Bristol-Myers Squibb is involved with the patents analyzed here, suggesting a potential licensing or development agreement, or that the patent was assigned to BMS through acquisition or other means. For clarity, the analysis will focus on the patent's claims and landscape, irrespective of the specific commercial rights holder.
The patent protection timeline for ubrogepant, including its various patent filings, is complex and involves several layers:
- Composition of Matter Patents: These are the foundational patents that protect the chemical compound itself. The earliest patents for ubrogepant likely date back to its discovery and initial synthesis. For example, related patents may have been filed in the early to mid-2000s.
- Formulation Patents: These patents protect specific drug formulations, such as tablets, capsules, or specific excipient combinations designed to improve drug delivery or stability.
- Process Patents: These patents protect the methods used to synthesize or manufacture the drug.
- Polymorph Patents (like U.S. Patent 11,540,981): These patents protect specific crystalline forms of the API that offer advantages in stability, solubility, or manufacturing.
U.S. Patent 11,540,981 was granted on January 3, 2023. Under U.S. patent law, utility patents generally have a term of 20 years from the date on which the application was filed, subject to the payment of maintenance fees. However, patent term extensions (PTEs) can be granted for pharmaceutical patents to compensate for delays caused by the regulatory review process (e.g., FDA approval).
The effective expiration date for a given patent depends on its filing date and any PTE. Ubrogepant (Ubrelvy) received FDA approval on December 23, 2019. This approval date is a critical factor for any potential PTE. Patents filed in the early stages of drug development, if eligible for PTE, could have their expiry extended.
Analyzing the specific filing dates for the patents that led to U.S. Patent 11,540,981 and any associated PTEs is essential for determining its precise expiration date and the duration of its protection. Without the exact filing date of the application that matured into 11,540,981 and information on any PTE granted, an exact expiry date cannot be provided. However, a patent filed around the discovery of ubrogepant, with a typical PTE, could potentially extend exclusivity well into the 2030s.
How Does This Patent Fit into the Broader CGRP Antagonist Landscape?
The development of CGRP receptor antagonists has been a significant area of innovation in migraine treatment over the past decade. U.S. Patent 11,540,981 exists within a highly competitive patent landscape involving multiple pharmaceutical companies.
Key players and their approaches in the CGRP antagonist space include:
- Small Molecule Antagonists (Gepants): These target the CGRP receptor directly. Ubrogepant (Ubrelvy by AbbVie, though patents analyzed are assigned to BMS) is a prime example. Other gepants include rimegepant (Nurtec ODT by Biohaven Pharmaceuticals, now Pfizer), zavegepant (Zavzpret by Biohaven Pharmaceuticals/Pfizer), and atogepant (Qulipta by AbbVie) for migraine prevention. The patent landscape here is dense with patents covering the API, specific salt forms, crystalline forms, formulations, and manufacturing processes.
- Monoclonal Antibodies (mAbs): These target the CGRP ligand or its receptor. Examples include erenumab (Aimovig by Amgen/Novartis), fremanezumab (Ajovy by Teva Pharmaceuticals), and galcanezumab (Emgality by Eli Lilly and Company). These antibodies have their own distinct patent portfolios, primarily focused on the antibody sequences, production methods, and therapeutic uses.
Competitive Patent Strategies:
Companies in this space employ multifaceted patent strategies to secure market exclusivity. This includes:
- Layering Patents: Filing for patents on the core molecule, then on novel crystalline forms, specific formulations, and improved manufacturing processes. This creates a "patent thicket" that can deter generic entry.
- Focus on Differentiated Forms: As seen with U.S. Patent 11,540,981, developing and patenting specific crystalline forms is a common tactic. These forms can offer tangible advantages over amorphous or other crystalline states.
- Targeting Different Indications: Patents are also sought for the use of CGRP antagonists in preventive treatment versus acute treatment, or for other related headache disorders.
Challenges for Competitors:
Generic manufacturers seeking to enter the market for ubrogepant will need to navigate this complex patent landscape. They must:
- Avoid Infringement: Ensure their generic product does not infringe on any active patents, including those covering specific crystalline forms, formulations, or manufacturing processes.
- Challenge Patents: Attempt to invalidate existing patents through litigation, arguing they are not novel, obvious, or adequately described.
- Develop Non-Infringing Alternatives: Create their own generic versions using different, non-infringing crystalline forms, formulations, or manufacturing methods. This is often challenging if the core API patents are still in force.
The existence of U.S. Patent 11,540,981, protecting specific crystalline forms of ubrogepant, adds another layer of protection for the drug. Generic companies must demonstrate that their product does not utilize these patented forms or that these patents are invalid. The detailed nature of the PXRD data in the patent's claims provides clear markers for potential infringement.
What Are the Potential Implications for Generic Entry?
The issuance of U.S. Patent 11,540,981 has direct implications for the timeline and feasibility of generic entry for ubrogepant.
- Extended Exclusivity: This patent, if it remains valid until its expiration, will extend the period of market exclusivity for ubrogepant. Generic manufacturers cannot market a product that infringes on these claims.
- Complexity for Biosimilar/Generic Development: Developing a generic version of a drug with extensive patent protection, particularly including patents on specific crystalline forms, requires careful formulation development. Generic companies must produce a product that is bioequivalent and does not infringe on any active patents. This may involve extensive research to identify alternative, non-infringing crystalline forms or to successfully challenge the validity of the existing polymorph patents.
- Litigation Risk: Generic companies often initiate Paragraph IV certifications under the Hatch-Waxman Act, challenging the validity or non-infringement of listed patents. The existence of a detailed polymorph patent like 11,540,981 can be a significant hurdle in such litigation. A successful defense of this patent by the brand manufacturer would block generic entry until its expiry.
- Strategic Importance of Polymorph Patents: Polymorph patents are increasingly utilized as a strategy to extend drug exclusivity. They are often filed after the initial composition of matter patents and can be crucial in preventing generic competition, even if the original patent for the active ingredient is nearing expiration.
The specific number of patented crystalline forms (25 claims, covering multiple distinct Forms I through XXIV) suggests a comprehensive effort to cover various stable and potentially advantageous crystalline states of ubrogepant. This broad coverage increases the difficulty for generic competitors seeking to formulate their own non-infringing product.
Key Takeaways
- U.S. Patent 11,540,981 protects specific crystalline forms of ubrogepant, a CGRP receptor antagonist for migraine treatment, through detailed claims based on Powder X-ray Diffraction (PXRD) patterns.
- The patent, granted on January 3, 2023, to Bristol-Myers Squibb Company, aims to extend market exclusivity for ubrogepant beyond its composition of matter patent protection.
- Specific crystalline forms can offer advantages in drug stability, bioavailability, and manufacturing, making them patentable and strategically important for pharmaceutical companies.
- The patent landscape for CGRP antagonists is competitive, with multiple companies employing layered patent strategies, including composition of matter, formulation, process, and polymorph patents.
- U.S. Patent 11,540,981 adds a significant layer of complexity for generic manufacturers seeking to enter the market, requiring them to avoid infringement of these specific crystalline forms or successfully challenge their validity.
Frequently Asked Questions
-
When does U.S. Patent 11,540,981 expire?
The expiration date depends on the original filing date of the patent application and any applicable Patent Term Extensions (PTEs). Without the precise filing date and PTE information, an exact expiry cannot be determined, but it extends protection beyond the initial composition of matter patent.
-
Can a generic version of ubrogepant be developed if it uses a different crystalline form?
Yes, if a generic manufacturer can develop a bioequivalent version of ubrogepant using a crystalline form that does not infringe on the claims of U.S. Patent 11,540,981, and all other relevant patents, it may be able to enter the market. This requires careful formulation development and a thorough freedom-to-operate analysis.
-
What are the advantages of patenting specific crystalline forms of a drug?
Patenting specific crystalline forms can provide improved stability, enhanced bioavailability, and more efficient manufacturing processes for a drug. These advantages can lead to a stronger therapeutic product and a longer period of market exclusivity for the patent holder.
-
Does this patent prevent all forms of ubrogepant from being manufactured?
No, this patent specifically protects the identified crystalline forms of ubrogepant as defined by their PXRD patterns. It does not necessarily preclude the existence or manufacture of other known or novel crystalline forms, amorphous forms, or different salt forms of ubrogepant, provided they do not infringe on other existing patents.
-
Who is the current commercial owner of ubrogepant (Ubrelvy)?
Ubrogepant (Ubrelvy) was originally developed by Allergan, which was acquired by AbbVie. Therefore, AbbVie is the current commercial owner of Ubrelvy. The patent analyzed (U.S. Patent 11,540,981) is assigned to Bristol-Myers Squibb Company.
Citations
[1] Bristol-Myers Squibb Company. (2023). U.S. Patent No. 11,540,981. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
